




Closed Trial – status update

ALIENOR

GINECO-OV222/ENGOT-OV7



Trial setting: **Sex chord-stromal ovarian tumors**

Study Design: **Randomized, open label, phase II trial**

Sponsor(s): **ARCAGY-GINECO**

Final No. of patients: **60**

Timeline (first patient – trial closing): **Feb 2013- Aug 2021**


Publications:

Planned publications: **Q3 2017**

Planned substudies:



ALIENOR Recruitment






International Collaboration



ALIENOR

RANDOMISED PATIENTS






Closed Trial – status update

ALIENOR

GINECO-OV222/ENGOT-OV7



Next steps :

- Primary analysis (Q2-Q3 2017) for primary endpoint (ASCO 2018)
- Secondary endpoints PFS, PFS2, cross-over, OS...

Ancillary studies :

- Translational 50/60 tumor blocks already available 😊
- Substudies

